Weifa AS – Norway’s largest fully-integrated pharmaceutical company - has chosen BizViewin order to simplify their budgeting processes and related reporting requirements.
Weifa needed a user-friendly but very flexible system to manage the budgeting process across the company with reliability for the process and quality of data. BizView will interact with Weifa’s financial system and complement the data warehouse recently introduced in the organization.
With BizView we will achieve total control of the budgeting process for all involved users on every level. It is as easy to work with as Excel, but without all the traditional pitfalls you could encounter with Excel says CFO Per Torgeir Sønsterud at Weifa. For us it was also important that BizView is a very adoptable system which we potentially could use for other purposes than just budgeting he adds.
The advantage with BizView is the user friendliness combined with extreme flexibility, all served in an affordable package which could be implemented in a few weeks says Henning Mork in NCG Group.
About BizView and NCG Group
BizView is one of the leading systems for forecasting, budgeting and reporting in the Nordic countries. The software provides a web-based Excel-like user interface combined with powerful workflow management. BizView is an open solution that also fits well with QlikView’s and Microsoft’s business intelligence offerings. BizView is developed and marketed by NCG Group with offices in Stockholm, Oslo and development in Skellefteå. NCG Group has more than 500 customers where over 1000 companies use our solutions.
For more information see www.ncg-group.com
Weifa is Norway’s leading fully-integrated pharmaceutical company with a history tracing back more than 70 years. The manufacturing plant is located in Kragerø whilst the head office is in Oslo. Annual turnover is around 500 MNOK. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. Weifa is also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa also has a considerable international business and is a leading producer of active ingredients for diabetes medicine and opiates for use in pain relief and cough medicine. 40 per cent of the turnover comes from our international business, where the customers are leading global pharmaceutical companies.
For more information see www.weifa.no